How Do CROs Choose a Clinical Trial Recruitment Vendor?

CROs buy recruitment differently than sponsors do. A sponsor is protecting a molecule and a timeline. A CRO is protecting a commitment it already made to the sponsor, usually with a contracted enrollment curve attached. That changes what matters in the vendor evaluation.

1. Predictability over peak performance A vendor who delivers steadily is worth more than one who occasionally spikes. CRO project managers are reporting weekly. A partner whose output swings unpredictably makes those calls miserable regardless of the monthly total.

2. Documentation discipline Every patient-facing asset needs IRB approval. Every screening script needs version control. Every consent-adjacent communication needs to survive an audit. Vendors who treat this as an afterthought create regulatory exposure that lands on the CRO, not the sponsor.

3. Speed to launch If the study is already behind, a vendor who needs eight weeks to produce creative and get materials approved is not a rescue. CROs ask hard questions about pre-approved template libraries and typical IRB turnaround for exactly this reason.

4. Site relationships CROs own the site relationships and do not want a vendor damaging them. A recruitment partner who dumps unqualified referrals on coordinators creates complaints that flow straight back to the CRO's clinical operations team.

5. Escalation clarity When enrollment slips, who gets called, how fast, and what authority do they have to change the plan? Vague answers here are disqualifying.

Data handling and privacy practices, in writing, including where patient information is stored Whether the vendor's screening constitutes a regulated activity in the jurisdictions involved Insurance and indemnity terms Subcontractor disclosure, because many "vendors" are brokers Continuity if the assigned account team leaves

The pitch that works and the one that does not

Vendors often lead with reach: audience size, channel breadth, impressions available. CRO evaluators generally discount all of it. What earns attention is a clear account of the operational chain, honest discussion of screen-failure rates in similar indications, and a specific remediation playbook for underperforming sites.

The other thing that lands well is candor about what the vendor will not do. A partner who says "we will not hit that curve with these criteria, and here is why" is more valuable than one who agrees to everything and renegotiates in month three.

The healthiest arrangement keeps the CRO owning site management and the recruitment partner owning the patient funnel up to the scheduled visit. Responsibilities stay clean, and nobody spends the weekly call arguing about lead quality.

If you are a CRO evaluating partners for a study that is already behind curve, contact our team or request a proposal with the protocol and current enrollment data.